We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $177M
1-Year Est. Return 91.13%
This Fund
S&P 500
This Quarter Est. Return
+16.86%
1 Year Est. Return
+91.13%
3 Year Est. Return
+230.7%
5 Year Est. Return
+260.67%
10 Year Est. Return
+2,169.5%
AUM
$177M
AUM Growth
-$72.5M
Cap. Flow
+$12.6M
Cap. Flow %
7.11%
Top 10 Hldgs %
44.39%
Holding
107
New
24
Increased
24
Reduced
27
Closed
20

Top Buys

Rank Stock Value
1
ELOX
Eloxx Pharmaceuticals
ELOX
+$5.07M
2
EDSA icon
Edesa Biotech
EDSA
+$3.85M
3
INDV icon
Indivior Pharmaceuticals
INDV
+$3.63M
4
CABA icon
Cabaletta Bio
CABA
+$2.85M
5
MSLE
Satellos Bioscience
MSLE
+$2.69M

Top Sells

Rank Stock Value
1
TENX icon
Tenax Therapeutics
TENX
+$4.03M
2
ZVRA icon
Zevra Therapeutics
ZVRA
+$2.46M
3
XOMA
Xoma
XOMA
+$2.18M
4
ABEO icon
Abeona Therapeutics
ABEO
+$1.04M
5
IKT icon
Inhibikase Therapeutics
IKT
+$1M

Sector Composition

Rank Sector Weight
1 Healthcare 74.11%
2 Miscellaneous 25.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRZN icon
101
Surrozen
SRZN
$265M
– –
-33,005
Closed -$961K
TERN
102
CALL
DELISTED
Terns Pharmaceuticals
TERN
– –
-100,000
Closed -$5.27M
VRCA icon
103
Verrica Pharmaceuticals
VRCA
$92.1M
– –
-99,735
Closed -$528K
XBI icon
104
CALL
State Street SPDR S&P Biotech ETF
XBI
$11.7B
– –
-400,000
Closed -$51.1M
XBI icon
105
PUT
State Street SPDR S&P Biotech ETF
XBI
$11.7B
– –
-400,000
Closed -$51.1M
XERS icon
106
Xeris Biopharma Holdings
XERS
$1.57B
– –
-40,030
Closed -$256K
XOMA
107
DELISTED
Xoma
XOMA
– –
-69,500
Closed -$2.18M
1 2 3 4
5

Similar funds

RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
MSA
Marathon Strategic Advisors Pittsburgh, Pennsylvania $177M AUM 66.85% 1-Year Est. Return
HF
Holcombe Financial Atlanta, Georgia $177M AUM 13.35% 1-Year Est. Return
BFAG
Blackston Financial Advisory Group The Villages, Florida $177M AUM 21.44% 1-Year Est. Return
CWP
Clark Wealth Partners O'fallon, Illinois $177M AUM 22.36% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
CMP
Christine Messmer PC Collegeville, Pennsylvania $177M AUM
JESC
J.E. Simmons & Co Dallas, Texas $177M AUM

Stonepine Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, Stonepine Capital Management held 107 positions worth $177M, down 29% from $250M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Stonepine Capital Management deployed $12.6M of net new capital in Q2 2026, opening 24 new positions and adding to 24 existing holdings. Its largest new stake was Eloxx Pharmaceuticals: 397,160 shares worth $5.51M.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, up from 46% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Tenax Therapeutics, an estimated $4.03M trimmed.

  • Stonepine Capital Management's largest Q2 2026 buy was Eloxx Pharmaceuticals: 397,160 shares worth $5.51M.
  • Stonepine Capital Management added most to Edesa Biotech in Q2 2026, an estimated $3.85M increase.
  • Stonepine Capital Management's biggest Q2 2026 reduction was Tenax Therapeutics, cutting an estimated $4.03M.
  • Stonepine Capital Management fully exited Xoma in Q2 2026, selling an estimated $2.18M.
  • Stonepine Capital Management's ten largest holdings make up 44% of its $177M portfolio in Q2 2026.
  • Stonepine Capital Management opened 24 new positions and closed 20 in Q2 2026.
  • Stonepine Capital Management's portfolio value fell 29% quarter-over-quarter to $177M.

Based on Stonepine Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.